Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

May 25, 2004

Study Completion Date

May 25, 2004

Conditions
Blepharospasm
Interventions
BIOLOGICAL

Botulinum toxin type A

Trial Locations (14)

10032

Columbia-Presbyterian Medical Center, New York

19107

Wills Eye Hospital, Philadelphia

27705

Duke University Medical Center, Durham

32504

Plastic Eye Surgery Association, Pensacola

32610

McKnight Brain Institute, Gainesville

43215

Ophthlamic Surgeons and Consultants of Ohio, Inc, Columbus

48105

Kellogg Eye Center, Ann Arbor

60612

Rush Presbyterian/St Luke's Medical Center, Chicago

77030

Parkinson's Disease Center and Movement Disorders Clinic, Houston

84102

Center for Facial Appearances, Salt Lake City

85006

Banner Health Research Institute, Phoenix

85013

Neurological Institute, Phoenix

90095

UCLA/Jules Stein Eye Institute, Los Angeles

92708

The Parkinson's and Movement Disorder Institute, Fountain Valley

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00234507 - Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm | Biotech Hunter | Biotech Hunter